Mooney R A, Swicegood C L, Marx R B
Endocrinology. 1986 Nov;119(5):2240-8. doi: 10.1210/endo-119-5-2240.
In digitonin-permeabilized adipocyte suspensions, adenylate cyclase activation was analyzed by an in situ assay and compared to lipolytic activity which was determined under essentially identical assay conditions. This approach permitted direct comparison of the regulatory responses of these two processes. Adenylate cyclase was activated by isoproterenol in permeabilized adipocytes, but digitonin caused a decrease in sensitivity to the beta-agonist. On the other hand, activation of adenylate cyclase by forskolin and NaF was unaffected by digitonin. Inhibition of isoproterenol-activated adenylate cyclase by propranolol was also unaffected by digitonin. These observations are consistent with a partial uncoupling by digitonin of the interaction between occupied beta-adrenergic receptors and the stimulatory GTP-binding component (Ns). Despite permeabilization, adenylate cyclase activity retained the capability to activate the lipolytic pathway. Activation of adenylate cyclase and lipolysis by isoproterenol was first detectable at 10(-8) M. At 10(-7) M isoproterenol, when the cyclase activity increase was 11 pmol cAMP formed/min X 10(6) cells (21% increase over basal), lipolysis was increased 153%. Forskolin was a more effective activator of adenylate cyclase than isoproterenol, increasing activity maximally by greater than 7-fold in contrast to a maximum of 4.5-fold activation by the beta-agonist. Forskolin-dependent adenylate cyclase activity increased by 63 pmol cAMP/min X 10(6) cells, however, before an increase in lipolysis was first detected (33% increase). Thus, cAMP generated by the two lipolytic agents was not identical in its lipolytic potential. Maximum rates of lipolysis were equal for the two agents. Insulin (10(-9) M) exerted an antilipolytic effect on lipolysis in permeabilized adipocytes whether the lipolytic activator was isoproterenol or forskolin. At 10(-6) and 10(-4) M isoproterenol, the magnitudes of the antilipolytic effect were 35% and 21%, respectively, whereas forskolin-activated lipolysis (at 10(-6) M) was inhibited 22%. Insulin had no effect on adenylate cyclase activity stimulated by either agent and assayed under essentially identical conditions. In summary, direct comparison of adenylate cyclase activity and lipolysis in digitonin-permeabilized adipocytes demonstrated a more efficient coupling of adenylate cyclase to lipolysis when the enzyme was activated by isoproterenol rather than forskolin. Additionally, the antilipolytic effect of insulin was preserved in the permeabilized adipocytes, but this effect did not involve inhibition of adenylate cyclase.
在洋地黄皂苷通透化的脂肪细胞悬液中,通过原位测定法分析腺苷酸环化酶的激活情况,并与在基本相同的测定条件下测定的脂解活性进行比较。这种方法允许直接比较这两个过程的调节反应。在通透化的脂肪细胞中,异丙肾上腺素可激活腺苷酸环化酶,但洋地黄皂苷会导致对β-激动剂的敏感性降低。另一方面,福斯高林和氟化钠对腺苷酸环化酶的激活不受洋地黄皂苷的影响。普萘洛尔对异丙肾上腺素激活的腺苷酸环化酶的抑制作用也不受洋地黄皂苷的影响。这些观察结果与洋地黄皂苷使占据的β-肾上腺素能受体与刺激性GTP结合成分(Ns)之间的相互作用部分解偶联一致。尽管细胞已通透化,但腺苷酸环化酶活性仍保留激活脂解途径的能力。异丙肾上腺素对腺苷酸环化酶和脂解的激活在10^(-8) M时首次可检测到。在10^(-7) M异丙肾上腺素时,当环化酶活性增加为11 pmol cAMP形成/分钟×10^6个细胞(比基础值增加21%)时,脂解增加了153%。福斯高林是比异丙肾上腺素更有效的腺苷酸环化酶激活剂,与β-激动剂最大4.5倍的激活相比,其最大活性增加超过7倍。然而,在首次检测到脂解增加(增加33%)之前,依赖福斯高林的腺苷酸环化酶活性增加了63 pmol cAMP/分钟×10^6个细胞。因此,两种脂解剂产生的cAMP在其脂解潜力方面并不相同。两种试剂的最大脂解速率相等。胰岛素(10^(-9) M)对通透化脂肪细胞中的脂解具有抗脂解作用,无论脂解激活剂是异丙肾上腺素还是福斯高林。在10^(-6) M和10^(-4) M异丙肾上腺素时,抗脂解作用的幅度分别为35%和21%,而福斯高林激活的脂解(在10^(-6) M时)被抑制了(22%)。胰岛素对两种试剂刺激的腺苷酸环化酶活性在基本相同的条件下测定时没有影响。总之,在洋地黄皂苷通透化的脂肪细胞中对腺苷酸环化酶活性和脂解的直接比较表明,当该酶由异丙肾上腺素而非福斯高林激活时,腺苷酸环化酶与脂解的偶联更有效。此外,胰岛素的抗脂解作用在通透化的脂肪细胞中得以保留,但这种作用不涉及对腺苷酸环化酶的抑制。